鼻腔NK/T細胞淋巴瘤三度空間立體順形放射治療成果：臺灣單一機構研究: Treatment Outcome following Three-dimensional Conformal Radiation Therapy (3D-CRT) for NK/T-cell Lymphoma of Nasal Cavity: A Single Institute Survey in Taiwan.

Purpose: To evaluate the treatment outcome following three-dimensional conformal radiotherapy (3D-CRT) for NK/T-cell lymphoma of nasal cavity.
Materials and Methods: Between August 2000 and March 2005, 11 patients had NK/T-cell lymphomas of nasal cavity diagnosed by histopathologic characteristics and typical immunophenotype. There were 5 males and 6 females, patients with age ranged from 27 years to 90 years (median, 57 years). Five patients were scheduled to receive 4-6 cycles of CHOP (cyclophosphamide, doxorubicin, vincrinstine and prednisolone) followed by radiotherapy. Three patients received 3 cycles of neo-adjuvant CHOP, radiotherapy, and 3 cycles of CHOP adjuvant. We excluded two patients who were dead during our radiotherapy course. All patients received 3D-CRT. The planned 3D-CRT dose was 50.4-54.0 Gy / 28-30 fractions.
Results: The median time of follow-up was 24.9 months (range 4 to 75 months). Seven (78%) of nine patients achieved complete remission (CR). The 2-year overall survival (OS) rate was 79%. Two patients expired in the first year. The 2-year local control and distant metastasis-free rates were 89% and 79%, respectively. The clinical factors predicting worse survival in univariate analysis were as follows: advanced Ann Arbor stage (p=0.005), B symptom (p=0.005), and higher International Prognostic Index scores (p=0.005). In the stage IE group, 7 of 8 patients (88%) achieved CR. The 2-year OS rate was 88%. The side effects of 3D-CRT were temporary and acceptable.
Conclusion: In our experience, the treatment policy for NK/T cell lymphoma of nasal cavity using 3D-CRT with greater than 50 Gy to gross tumor/tumor bed plus adequate margin was feasible.